Pulmatrix (NASDAQ:PULM) Shares Cross Below 50 Day Moving Average – Time to Sell?

Shares of Pulmatrix, Inc. (NASDAQ:PULM) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.59 and traded as low as $1.23. Pulmatrix shares last traded at $1.27, with a volume of 17,598 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Pulmatrix Trading Down 1.6%

The company has a 50 day moving average of $1.56 and a 200 day moving average of $2.73. The firm has a market cap of $4.56 million, a price-to-earnings ratio of -0.89 and a beta of 1.94.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).